Patents Examined by Brenda Coleman
  • Therapeutic compounds and compositions
    Patent number: 8785450
    Abstract: Compounds and compositions comprising compounds that modulate pyruvate kinase M2 (PKM2) are described herein. Also described herein are methods of using the compounds that modulate PKM2 in the treatment of cancer.
    Type: Grant
    Filed: June 29, 2010
    Date of Patent: July 22, 2014
    Assignee: Agios Pharmaceuticals, Inc.
    Inventors: Francesco G. Salituro, Jeffrey O. Saunders, Shunqi Yan
  • Dye, photoelectric conversion element using the same, photoelectrochemical cell, and method of producing dye
    Patent number: 8779126
    Abstract: A dye, having a structure represented by formula (1A): wherein A represents a group of atoms necessary for forming a ring together with the carbon-nitrogen bond; at least one of Y1A and Y2A represents an acidic group, in which when they each represent an acidic group, they may be the same as or different from each other, or when only one of them represents an acidic group, the other represents an electron-withdrawing group; D represents a group to give a dye; n represents an integer of 1 or greater; L represents a single bond or a divalent linking group; and Y3A represents an acidic group.
    Type: Grant
    Filed: October 29, 2009
    Date of Patent: July 15, 2014
    Assignee: Fujifilm Corporation
    Inventors: Katsumi Kobayashi, Keizo Kimura, Tatsuya Susuki, Hirotaka Satou, Yukio Tani
  • Dihydro-oxazolobenzodiazepinone compounds, a process for there preparation and pharmaceutical compositions containing them
    Patent number: 8778932
    Abstract: Compounds of formula (I): wherein: R1 represents a hydrogen atom or an alkyl group; R2 represents an alkyl group; R3 represents an aryl or heteroaryl group. Medicinal products containing the same which are useful in the treatment or prevention of psychiatric and neurological disorders characterized by cognitive deficits.
    Type: Grant
    Filed: March 7, 2012
    Date of Patent: July 15, 2014
    Assignees: Les Laboratoires Servier, Egis Gyogyszergyar Nyrt
    Inventors: István Ling, József Barkóczy, Ferenc Antoni, István Gascályi, György Lévay, Michael Spedding, László Hársing
  • Substituted heteroaryl inhibitors of B-RAF
    Patent number: 8778929
    Abstract: The present invention relates to new compounds of general formula (I), wherein the groups R1 to R3, X1, X2, X3 and L1 are defined as in claim 1, which are suitable for the treatment of diseases characterised by excessive or abnormal cell proliferation, and the use thereof in such a treatment.
    Type: Grant
    Filed: September 28, 2009
    Date of Patent: July 15, 2014
    Assignee: Boehringer Ingelheim International GmbH
    Inventors: Steffen Steurer, Peter Ettmayer, Andreas Mantoulidis
  • Compounds for treating disorders mediated by metabotropic glutamate receptor 5, and methods of use thereof
    Patent number: 8772301
    Abstract: Provided herein are compounds and methods of synthesis thereof. The compounds set forth herein are useful for the treatment, prevention, and/or management of various disorders, such as neurological disorders, neurodegenerative disorders, neuropsychiatric disorders, disorders of cognition, learning or memory, gastrointestinal disorders, lower urinary tract disorder, and cancer. Compounds set forth herein modulate the activity of metabotropic glutamate receptor 5 (mGluR5) in the central nervous system or the periphery. Pharmaceutical formulations containing the compounds and their methods of use are also provided herein.
    Type: Grant
    Filed: December 17, 2010
    Date of Patent: July 8, 2014
    Assignee: Sunovion Pharmaceuticals, Inc.
    Inventors: Larry Wendell Hardy, Michele L. R. Heffernan, Frank Xinhe Wu, Kerry L. Spear, Lakshmi D. Saraswat
  • Carbazole compounds and therapeutic uses of the compounds
    Patent number: 8765738
    Abstract: Compounds of the general structural formula (I) and (II) and use of the compounds and salts and hydrates thereof, as therapeutic agents are disclosed. Treatable diseases and conditions include cancers, inflammatory diseases and conditions, and immunodeficiency diseases.
    Type: Grant
    Filed: October 5, 2009
    Date of Patent: July 1, 2014
    Assignee: Incuron, LLC
    Inventors: John Tucker, Sergey Sviridov, Leonid Brodsky, Catherine Burkhart, Andrei Purmal, Katerina Gurova, Andrei Gudkov
  • Gamma secretase modulators
    Patent number: 8759337
    Abstract: This invention provides novel compounds that are modulators of gamma secretase. The compounds have the formula (Chemical formula should be inserted here as it appears on abstract in paper form). Also disclosed are methods of modulating gamma secretase activity and methods of treating Alzheimer's Disease using the compounds of formula (I).
    Type: Grant
    Filed: December 18, 2009
    Date of Patent: June 24, 2014
    Assignee: Merck Sharp & Dohme Corp.
    Inventors: Theodros Asberom, Xianhai Huang, Zhaoning Zhu, John W. Clader, Dmitri A. Pissarnitski, Hubert B. Josien, Hongmei Li
  • Compositions and methods for treatment of cancer
    Patent number: 8754078
    Abstract: The present invention relates to pyrroloquinolinyl-pyrrolidine-2,5-dione compounds in combination with chemotherapeutic agents. The present invention provides methods of treating a cell proliferative disorder, such as a cancer, by administering to a subject in need thereof a therapeutically effective amount of a pyrroloquinolinyl-pyrrole-2,5-dione compound or pyrroloquinolinyl-pyrrolidine-2,5-dione compound of the present invention and also administering a effective amount of a chemotherapeutic agent.
    Type: Grant
    Filed: February 7, 2013
    Date of Patent: June 17, 2014
    Assignee: ArQule, Inc.
    Inventors: Chiang J. Li, Mark A. Ashwell, Jason Hill, Magdi M. Moussa, Neru Munshi
  • 1,4-oxazepines as BACE1 and/or BACE2 inhibitors
    Patent number: 8748418
    Abstract: The present invention relates to 1,4-Oxazepines of formula I having BACE1 and/or BACE2 inhibitory activity, their manufacture, pharmaceutical compositions containing them and their use as therapeutically active substances. The active compounds of the present invention are useful in the therapeutic and/or prophylactic treatment of e.g. Alzheimer's disease and type 2 diabetes.
    Type: Grant
    Filed: March 9, 2012
    Date of Patent: June 10, 2014
    Assignee: Hoffmann-La Roche Inc.
    Inventors: Emanuele Gabellieri, Wolfgang Guba, Hans Hilpert, Harald Mauser, Alexander V. Mayweg, Mark Rogers-Evans, Didier Rombach, Andrew Thomas, Thomas Woltering, Wolfgang Wostl
  • Process for the preparation of histamine H3 receptor modulators
    Patent number: 8748596
    Abstract: The present invention is directed to novel processes for the preparation of histamine H3 receptor modulators, in the treatment of for example, cognitive disorders, sleep disorders and/or psychiatric disorders.
    Type: Grant
    Filed: March 17, 2010
    Date of Patent: June 10, 2014
    Assignee: Janssen Pharmaceutica NV
    Inventors: Diego Broggini, Vit Lellek, Susanne Lochner, Neelakandha S. Mani, Adrian Maurer, Daniel J. Pippel, Lana K. Young
  • N-substituted noribogaine prodrugs
    Patent number: 8741891
    Abstract: This invention relates generally to prodrugs of noribogaine. This invention also relates to pharmaceutical compositions comprising the prodrugs of noribogaine as well as method of treating pain, addiction and/or stress using such compounds and/or pharmaceutical compositions.
    Type: Grant
    Filed: June 21, 2011
    Date of Patent: June 3, 2014
    Assignee: DemeRx, Inc.
    Inventor: Deborah C. Mash
  • Bicyclic compound, production and use thereof
    Patent number: 8741943
    Abstract: The present invention provides a new cyclic compound having a CCR antagonist activity, especially a CCR5 antagonist activity, and the use thereof. The compound of the present invention is represented by the formula: wherein, R1 is a 5- to 6-membered ring group which may be substituted; X1 is a bond or the like; ring A is a 5- to 6-membered ring group which may be substituted; ring B is a 8- to 10-membered ring group which may be substituted; X2 is a bivalent group of 1 to 4 atoms; Z1 is a bivalent cyclic ring group or the like; Z2 is a bond or the like; and R2 is an amino group, a nitrogen-containing heterocyclic group which may be substituted or the like, or a salt thereof.
    Type: Grant
    Filed: May 21, 2012
    Date of Patent: June 3, 2014
    Assignee: Tobira Therapeutics, Inc.
    Inventors: Mitsuru Shiraishi, Masanori Baba, Katsuji Aikawa, Naoyuki Kanzaki, Masaki Seto, Yuji Iizawa
  • Substituted amides, manufacturing and use thereof as medicaments
    Patent number: 8741890
    Abstract: The present invention relates to new substituted prolinamides of general formula (I) wherein D, Y, A, B, R3, R4 and R5 are defined as in the specification, the tautomers, the enantiomers, the diastereomers, the mixtures thereof and the salts thereof, particularly the physiologically acceptable salts thereof with inorganic or organic acids or bases, which have valuable properties.
    Type: Grant
    Filed: November 14, 2008
    Date of Patent: June 3, 2014
    Assignee: Boehringer Ingelheim International GmbH
    Inventors: Kai Gerlach, Herbert Nar, Henning Priepke, Annette Schuler-Metz, Wolfgang Wienen
  • Methods and compositions for preparing noribogaine from voacangine
    Patent number: 8742096
    Abstract: Disclosed are methods and compositions for preparing and purifying the non-addictive alkaloid noribogaine.
    Type: Grant
    Filed: March 14, 2012
    Date of Patent: June 3, 2014
    Assignee: DemeRx, Inc.
    Inventors: Robert M. Moriarty, Simon Mbua Ngale Efange
  • Crystalline forms of a pharmaceutical compound
    Patent number: 8729065
    Abstract: Described are crystalline forms of the pharmaceutical compound “[9S-(9?,10?,12?)]-5,16-Bis[(ethylthio)methyl]-2,3,9,10,11,12-hexahydro-10-hydroxy-9-methyl-1-oxo-9,12-epoxy-1H-diindolo[1,2,3-fg:3?,2?,1?-kl]pyrrolo[3,4-i][1,6]benzodiazocine-10-carboxylic acid methyl ester”, as well as methods for their use and preparation.
    Type: Grant
    Filed: January 3, 2011
    Date of Patent: May 20, 2014
    Assignee: Cephalon, Inc.
    Inventors: Michael Harold Rock, Heidi Lopez De Diego, Kim Lasse Christensen, Ole Nielsen, Anders Buur, Mark Howells
  • Heterocyclic compounds
    Patent number: 8722662
    Abstract: Provided is a compound having a monoamine reuptake inhibitory activity, which is represented by the formula (I) wherein ring A is an optionally substituted 6-membered aromatic ring, ring B is the substituents on ring A are optionally bonded to form, together with ring A, an optionally substituted 9- or 10-membered aromatic fused ring, and other symbols are as defined in the specification, or a salt thereof.
    Type: Grant
    Filed: October 5, 2011
    Date of Patent: May 13, 2014
    Assignee: Takeda Pharmaceutical Company Limited
    Inventors: Yuji Ishichi, Masami Yamada, Taku Kamei, Ikuo Fujimori, Yoshihisa Nakada, Tomoya Yukawa, Nobuki Sakauchi, Yusuke Ohba, Tetsuya Tsukamoto
  • Inhibitors of diacylglycerol acyltransferase
    Patent number: 8716312
    Abstract: The present invention relates to novel heterocyclic compounds as diacylglycerol acyltransferase (“DGAT”) inhibitors, pharmaceutical compositions comprising the heterocyclic compounds and the use of the compounds for treating or preventing a cardiovascular disease, a metabolic disorder, obesity or an obesity-related disorder, diabetes, dyslipidemia, a diabetic complication, impaired glucose tolerance or impaired fasting glucose.
    Type: Grant
    Filed: November 17, 2009
    Date of Patent: May 6, 2014
    Assignee: Merck Sharp & Dohme Corporation
    Inventors: Pauline C. Ting, Robert Aslanian, Mary Ann Caplen, Jianhua Cao, Tin-Yau Chan, David Kim, Hyunjin Kim, Jae-Hun Kim, Rongze Kuang, Joe F. Lee, John Schwerdt, Heping Wu, Nicolas Zorn
  • Thiophenyl and pyrrolyl azepines as serotonin 5-HTreceptor ligands and uses thereof
    Patent number: 8716276
    Abstract: The present invention generally relates to a series of compounds, to pharmaceutical compositions containing the compounds, and to use of the compounds and compositions as therapeutic agents. More specifically, compounds of the present invention are thiophenyl and pyrrolyl azepine compounds. These compounds are serotonin receptor (5-HT2c) ligands and are useful for treating diseases, disorders, and conditions wherein modulation of the activity of serotonin receptors (5-HT2c) is desired (e.g. addiction, anxiety, depression, obesity, and others).
    Type: Grant
    Filed: January 12, 2011
    Date of Patent: May 6, 2014
    Assignee: Athersys, Inc.
    Inventors: L. Nathan Tumey, David C. Bom, Youssef L. Bennani, Michael J. Robarge
  • Agents for preventing and treating disorders involving modulation of the ryanodine receptors
    Patent number: 8710045
    Abstract: The present invention provides compounds of Formula I and salts, hydrates, solvates, complexes, and prodrugs thereof. The present invention further provides methods for synthesizing compounds of Formula I. The invention additionally provides pharmaceutical compositions comprising the compounds of Formula I and methods of using the pharmaceutical compositions of Formula I to treat and prevent disorders and diseases associated with the RyR receptors that regulate calcium channel functioning in cells.
    Type: Grant
    Filed: November 2, 2010
    Date of Patent: April 29, 2014
    Assignee: The Trustees of Columbia University in the City of New York
    Inventors: Andrew Robert Marks, Donald W. Landry, Shixian Deng
  • Organic compounds
    Patent number: 8710216
    Abstract: The invention relates to a new crystalline form II of N-benzoyl-staurosporine; compositions containing the same; processes for the preparation thereof; and the use of crystalline form II of of N-benzoyl-staurosporine in diagnostic methods or therapeutic treatment of warm-blooded animals, especially humans. The invention relates to the amorphous forms of N-benzoyl-staurosporine; compositions containing the same; processes for the preparation thereof; and the use of amorphous N-benzoyl-staurosporine in diagnostic methods or therapeutic treatment of warm-blooded animals, especially humans.
    Type: Grant
    Filed: May 15, 2012
    Date of Patent: April 29, 2014
    Assignee: Novartis AG
    Inventors: Pascale Hoehn, Bernd Koch, Michael Mutz